HYALGAN 20MG/2ML INJECTION
| Product Name | Hyalgan 20 mg/2 ml Injection |
| Active Ingredient | Sodium Hyaluronate |
| Strength | 20 mg/2 ml |
| Dosage Form | Injection |
| Therapeutic Class | Viscosupplement / Joint Pain Relief |
| Indication | Osteoarthritis Pain Management |
| Administration Route | Intra-Articular |
| Packaging | Pre-filled Syringe |
| Storage | Store at 2°C–8°C, protect from light |
| Prescription | Required |
HYALGAN 20MG/2ML INJECTION
Hyalgan 20mg/2ml Injection is a high-quality viscosupplement used to manage pain and improve joint function in patients with osteoarthritis. It contains sodium hyaluronate, a natural polysaccharide that lubricates and cushions the joints, reducing friction and enhancing mobility. This pharmaceutical product is administered via intra-articular injection under medical supervision for safe and effective relief.
Hyalgan 20mg/2ml Injection works by restoring the natural viscosity and elasticity of synovial fluid in the joint, which helps reduce stiffness, swelling, and pain. It is commonly recommended for patients who do not respond adequately to oral pain relievers or physical therapy. Regular administration according to the prescribed schedule ensures long-lasting joint comfort and improved quality of life.
Hyalgan 20mg/2ml Injection guarantees purity, potency, and consistent therapeutic performance. These pharmaceutical products are widely supplied to hospitals, orthopedic clinics, and pharmacies, providing reliable and high-quality therapy for patients seeking effective osteoarthritis management.
Product Features
- Contains Sodium Hyaluronate 20 mg/2 ml
- Intra-articular injection for joint lubrication
- Used to relieve osteoarthritis pain and stiffness
- Supports improved joint mobility and function
- High-quality pharmaceutical injectable formulation
How It Helps
- Reduces joint pain and inflammation
- Restores synovial fluid viscosity
- Improves mobility and flexibility of joints
- Supports long-term osteoarthritis management

Reviews
There are no reviews yet.